Skip to main content

Advertisement

Table 1 Distribution of the responses in the 28-day trial

From: Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon

Year Treatment Number included Parasite clearance on day 3 (ITT) (%) Observed ACPR Lost to follow-up and excluded Reinfection ITT1 PP1
2005 AQ 64 87.5 50 5 5 50/64 (55/64) 50/59 (55/59)
  AS-AQ 60 100 43 6 10 43/60 (53/60) 43/54 (53/54)
  AS-SP 61 96.8 50 4 4 50/61 (54/61) 50/57 (54/57)
2006a AQ-SP 67 86.6 55 5 7 55/67 (62/67) 55/62 (62/62)
  AS-MQ 69 95.7 60 8 1 60/69 (61/69) 60/61 (61/61)
2006b AS-AQ 62 98.4 52 5 3 52/62 (55/62) 52/57 (55/57)
  AM-LM 61 100 58 1 2 58/61 (60/61) 58/60 (60/60)
2006c AS-CD 83 97.6 53 12 7 53/83 (60/83) 53/71 (60/71)
  AS-SP 85 100 73 6 1 73/85 (74/85) 73/79 (74/79)
2007 AS-AQ 92 99 73 4 8 73/92 (81/92) 73/88 (81/88)
  DH-PP 91 100 84 5 0 84/91 (84/91) 84/86 (84/86)
  1. 1Values in parentheses denote the observed proportions of ACPR after PCR correction in each treatment group. No recrudescence was observed with the AM-LM combination, and no re-infection was observed with DH-PP. ITT, intention-to-treat; PP, per protocol.